| Added by | llasorsa |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM |
| Creator | Belthier et al. |
| Author | Guillaume Belthier |
| Author | Zeinab Homayed |
| Author | Fanny Grillet |
| Author | Christophe Duperray |
| Author | Julie Vendrell |
| Author | Ilona Krol |
| Author | Sophie Bravo |
| Author | Jean-Christophe Boyer |
| Author | Olivia Villeronce |
| Author | Jihane Vitre-Boubaker |
| Author | Diana Heaug-Wane |
| Author | Françoise Macari-Fine |
| Author | Jai Smith |
| Author | Matthieu Merlot |
| Author | Thibault Mazard |
| Author | Fabienne Portales |
| Author | Jérôme Solassol |
| Author | Marc Ychou |
| Author | Nicola Aceto |
| Author | Emilie Mamessier |
| Author | François Bertucci |
| Author | Jean Marc Pascussi |
| Author | Emmanuelle Samalin |
| Author | Frédéric Hollande |
| Author | Julie Pannequin |
| Abstract | Circulating tumor cells (CTCs) are promising diagnostic and prognostic tools for clinical use. In several cancers, including colorectal and breast, the CTC load has been associated with a therapeutic response as well as progression-free and overall survival. However, counting and isolating CTCs remains sub-optimal because they are currently largely identified by epithelial markers such as EpCAM. New, complementary CTC surface markers are therefore urgently needed. We previously demonstrated that a splice variant of CD44, CD44 variable alternative exon 6 (CD44v6), is highly and specifically expressed by CTC cell lines derived from blood samples in colorectal cancer (CRC) patients. Two different approaches-immune detection coupled with magnetic beads and fluorescence-activated cell sorting-were optimized to purify CTCs from patient blood samples based on high expressions of CD44v6. We revealed the potential of the CD44v6 as a complementary marker to EpCAM to detect and purify CTCs in colorectal cancer blood samples. Furthermore, this marker is not restricted to colorectal cancer since CD44v6 is also expressed on CTCs from breast cancer patients. Overall, these results strongly suggest that CD44v6 could be useful to enumerate and purify CTCs from cancers of different origins, paving the way to more efficacious combined markers that encompass CTC heterogeneity. |
| Publication | Cancers |
| Volume | 13 |
| Issue | 19 |
| Pages | 4966 |
| Date | 2021-10-02 |
| Journal Abbr | Cancers (Basel) |
| Language | eng |
| DOI | 10.3390/cancers13194966 |
| ISSN | 2072-6694 |
| Library Catalog | PubMed |
| Extra | PMID: 34638450 PMCID: PMC8508506 |
| Tags | breast cancer, colorectal cancer, EMT, patient blood samples |
| Date Added | 2022/08/30 - 16:26:49 |
| Date Modified | 2024/10/10 - 16:53:54 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
